Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV000560303 | SCV000640420 | uncertain significance | Giant axonal neuropathy 1 | 2017-07-25 | criteria provided, single submitter | clinical testing | This sequence change replaces glutamic acid with lysine at codon 362 of the GAN protein (p.Glu362Lys). The glutamic acid residue is moderately conserved and there is a small physicochemical difference between glutamic acid and lysine. This variant is present in population databases (rs587779384, ExAC 0.006%). This variant has been reported as heterozygous in an individual affected with Charcot Marie Tooth disease, type 2 (PMID: 25025039). ClinVar contains an entry for this variant (Variation ID: 157535). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated, but these predictions have not been confirmed by published functional studies and their clinical significance is uncertain. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Dept. |
RCV000144881 | SCV000118592 | uncertain significance | Charcot-Marie-Tooth disease | 2013-11-01 | no assertion criteria provided | research |